For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
More than a year since the COVID-19 outbreak began, the pharmaceutical industry has shifted its focus to vaccine development for infectious diseases while continuing its pre-pandemic efforts to develop novel innovations to address unmet needs across a broad spectrum of indications. Large and small firms alike are now directing top talent and resources, including regulatory, to those efforts.
At the same time, companies cannot afford to neglect the mature products that provide the revenues to fund R&D. One way to balance these conflicting demands is to streamline the regulatory maintenance of approved products. By honing these five competencies, companies can manage post-marketing regulatory requirements better and more efficiently.
3 steps for making your CRO relationships more successful
Jul 29, 2021
The upward trend of FSP outsourcing
Sep 29, 2022
FSP 2.0: Why Talent Development is the New Talent Acquisition
Oct 26, 2022
Identifying the right FSP candidates on day one
Aug 9, 2021
EU-CTR: Preparing for trial transition
Nov 30, 2023
Biosimilar Development: Are therapeutic clinical trials needed?
Nov 16, 2021
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
What's the Future of FSP?
Jan 6, 2022
Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Jan 26, 2022
On-demand webinar: An expert guide to EU-CTR
Mar 10, 2022
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021